Jupiter Endovascular's SPIRARE II Trial Shows Promising Results for Pulmonary Embolism Treatment
Jupiter Endovascular, Inc. has announced positive results from its SPIRARE II pivotal trial, which evaluated the Vertex™ Pulmonary Embolectomy System for treating acute, intermediate-risk pulmonary embolism (PE). The trial, presented at EuroPCR 2026 in Paris, demonstrated that the system met its primary endpoints, showing significant heart recovery and clinical safety. The Vertex system, utilizing the Transforming Fixation (TFX) platform, is designed to navigate the right heart and stabilize in the pulmonary arteries for precise intervention. The trial involved 123 patients across Europe and the U.S., achieving a 0.39 mean reduction in RV/LV ratio and a 2.4% major adverse event rate. The system's ability to provide flexible navigation and stable support addresses challenges in PE thrombectomy, offering a minimally invasive procedure with a mean time of 40.2 minutes. 
